MorphoSys AG
XETRA:MOR
MorphoSys AG
XETRA:MOR
Price:
66.65 EUR
0.83%
Market Closed
Updated:
May 4, 2024
MorphoSys AG
Cash from Operating Activities
|
MorphoSys AG
Cash from Operating Activities Peer Comparison
Comparables:
BNTX
CVAC
IMTX
BIO
FYB
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
MorphoSys AG
XETRA:MOR
|
Cash from Operating Activities
-€295.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Operating Activities
€5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash from Operating Activities
-€267.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Operating Activities
€18.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Cash from Operating Activities
-€2.7m
|
CAGR 3-Years
46%
|
CAGR 5-Years
44%
|
CAGR 10-Years
9%
|
|
|
Formycon AG
XETRA:FYB
|
Cash from Operating Activities
-€18.9m
|
CAGR 3-Years
-134%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Cash from Operating Activities?
Cash from Operating Activities
-295.8m
EUR
-295.8m
EUR
Based on the financial report for Dec 31, 2023, MorphoSys AG's Cash from Operating Activities amounts to -295.8m EUR.
What is MorphoSys AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-55%
-55%
Over the last year, the Cash from Operating Activities growth was 19%.
You don't have any saved screeners yet
